Tuesday, March 5, 2013

Alembic gets approval for Extended Release version of Pfizer's depression Drug Desvenlafaxine (Pristiq) - Ranbaxy to Market in the US

Alembic has announced that it has received an NDA approval for extended release version of  Pfizer's anti depressant drug Pristiq. Pristiq sell approximately  $550m in the US. Alembic has outlicensed rights to  Ranbaxy for marketing in the US. The company will start marketing the product immediately.

Alembic will manufacture and supply the drug to Ranbaxy for marketing in the US. Assuming a 25 percent market share and 20 percent price discount to innovator, the drug should generate about $100million in annual sales. The post tax peak profitability could be as high as 60 percent. Assuming a  50 percent profit share which is usually the case, Alembic should get about $30million in profits and another 8  percent of sales in profits from manufacturing supplies.

We foresee the opportunity generating close to $150million in incremental cash flows for Alembic.

The marketing exclsuivity is expected until September 2015, when other generic copies of Pristiq can be expected.


Enter your email address:

Delivered by FeedBurner